Abstract：
Identifying typical doses of existing opioid use disorder medications, such as injectable opioid agonist treatment (iOAT), can support client and program needs, and potentially increase iOAT expansion. Longitudinal data from participants in a cohort study (n = 131), along with clinic dispensation records from August 2014 to April 2020, were used to examine physician prescribed as well as used doses of injectable diacetylmorphine and hydromorphone. Dosage groups, by medication and prescribed dose per session, were created for both hydromorphone and diacetylmorphine. A total of 534, 522 injections were registered during the study period among 129 participants. Mean received diacetylmorphine doses ranged from 106 to 989 mg per day, with most clients using 125-262 mg per session (mean 192.99 mg) and attending 2.40 sessions per day. Mean received hydromorphone doses ranged from 51.09 to 696.06 mg per day, with the majority using 88-154 mg per session (mean 121.32 mg; 2.43 sessions). Average daily doses remained stable overtime and, while mid-range doses were most typical, participants used the whole spectrum of allowable dose prescriptions. Evidence supporting typical doses of iOAT can be integrated into program planning to better allow providers and prescribers to anticipate program needs and engage in individualized care.
摘要：
确定现有阿片类药物使用障碍药物的典型剂量，例如可注射阿片类激动剂治疗（iOAT），可以支持客户和程序的需求，并可能增加iOAT的扩展。一项队列研究参与者的纵向数据(n=131)，我们使用2014年8月至2020年4月的临床配药记录来检查医生处方以及使用剂量的注射用二乙酰吗啡和氢吗啡酮.剂量组，按每次疗程的药物和处方剂量计算，为氢吗啡酮和二乙酰吗啡产生。在研究期间，129名参与者共登记了534、522次注射。平均接受二乙酰吗啡的剂量范围为每天106至989毫克，大多数客户每次使用125-262毫克（平均192.99毫克），每天参加2.40次会议。平均接受氢吗啡酮剂量范围为每天51.09至696.06毫克，大多数人每节使用88-154毫克（平均121.32毫克；2.43个疗程）。平均每日剂量保持稳定，虽然中等剂量是最典型的，参与者使用了整个允许剂量处方。支持iOAT典型剂量的证据可以整合到计划计划中，以更好地允许提供者和处方者预测计划需求并参与个性化护理。
